Immunological modifications following chemotherapy are associated with delayed recurrence of ovarian cancer.

ABSTRACT:

Introduction

Ovarian cancer recurs in most High Grade Serous Ovarian Cancer (HGSOC) patients, including initial responders, after standard of care. To improve patient survival, we need to identify and understand the factors contributing to early or late recurrence and therapeutically target these mechanisms. We hypothesized that in HGSOC, the response to chemotherapy is associated with a specific gene expression signature determined by the tumor microenvironment. In this study, we sought to determine the differences in gene expression and the tumor immune microenvironment between patients who show early recurrence (within 6 months) compared to those who show late recurrence following chemotherapy.

Methods

Paired tumor samples were obtained before and after Carboplatin and Ta

SUBMITTER: Adzibolosu N 

PROVIDER: S-EPMC10331425 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature